Clinical Trials Logo

Clinical Trial Summary

This study investigates the use of low-dose (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection, USP administered intramuscularly to healthy clinicians as part of an experiential learning practice within a psychedelic-assisted therapy (PAT) training program. The primary objective of this study is to test the hypothesis that competencies required for mental healthcare professionals providing PAT are enhanced by undergoing a single ketamine-assisted therapy experience, as part of a PAT training program. Primary outcomes of this study are self-reported measures of therapeutic efficacy and competency for providing both general and psychedelic-assisted therapy, measured at baseline and four weeks following an academic in-person retreat with optional ketamine administration. Secondary endpoints include measures of personality and magnitude of perceived mystical experiences. Individual changes in scores across time will be calculated, and differences in therapeutic efficacy and competency between clinician trainees who choose to participate in a personal ketamine-assisted therapy session and those who do not will be assessed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05468047
Study type Interventional
Source Integrative Psychiatry Institute
Contact
Status Not yet recruiting
Phase Early Phase 1
Start date September 2022
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT05042765 - Entheogen Resurgence
Enrolling by invitation NCT05592379 - Consciousness, Psilocybin, and Well-Being Phase 1
Completed NCT04842045 - Pilot RECAP Study in Healthy Volunteers Phase 1
Completed NCT04965740 - Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids
Not yet recruiting NCT06450210 - Safety for Home Administration of Microdose Psilocybin Use Phase 1
Recruiting NCT05698511 - Neural and Physiological Correlates of Psychedelic Sub-states Phase 1
Withdrawn NCT05252598 - Mood and Cognitive Effects of Psilocybin in Healthy Participants Early Phase 1
Terminated NCT04424225 - Visual Surround Suppression and Perceptual Expectation Under Psilocybin Phase 1
Not yet recruiting NCT05866471 - Pairing Psilocybin With Transcutaneous Auricular Vagus Nerve Stimulation Phase 1